FDA Adcomm to Tackle Complexity of CAR-T for Multiple Myeloma 3/15/2024

NASH or MASH: No Matter What You Call It, Madrigal’s FDA Approval Is a Big Deal 3/15/2024

BeiGene’s Tevimbra Wins First US Approval Following Tough Regulatory Path 3/15/2024

FDA Adcomm Backs Geron’s Anemia Drug for Blood Cancer 3/15/2024

FDA Approves Madrigal’s Rezdiffra as First MASH Therapy 3/15/2024

AstraZeneca announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases.

The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism.

AstraZeneca Boosts Rare Disease Portfolio with $1.05B Amolyt Acquisition 3/14/2024

BIO Boots WuXi AppTec from Trade Group Amid US National Security Concerns 3/14/2024

ADC Biotech Tubulis Closes Upsized $138M Financing Round 3/14/2024

Recently Laid Off? Contract Work Could Be an Attractive Option 3/14/2024

Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value 3/14/2024

Mirum Secures Livmarli’s Expansion into Familial Intrahepatic Cholestasis 3/14/2024

Merck to Start Trials of New HPV Vaccine and Single-Dose Gardasil Shot 3/14/2024

Career Coach: How to Truly Tailor a Resume 3/14/2024

PhRMA Loses Another Legal Battle as Court Sides with Arkansas Over Drug Discount Program 3/14/2024

The Unintended Consequences of Small Molecules 3/14/2024

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company's 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.

There are thousands of diseases worldwide with no cure or available treatments. Traditional drug discovery and development takes decades and billions of dollars and more than 90% of these drugs fail in clinical trials. The emergence of artificial intelligence (AI) holds promise for streamlining and improving the entire process. However, ushering in a new era of AI-driven drug discovery requires costly and lengthy validation in preclinical cell, tissue, and animal models and human clinical trials.

A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells. Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.

The researchers found that STAP-1 plays an important role in the activation of T cells, which are white blood cells that play a critical role in defending the body against infections and maintaining overall health.

A team of University of Michigan researchers has successfully modified a naturally occurring chemical compound in the lab, resulting in advanced lead compounds with anti-HIV activity.

Their results, published March 7 in the Journal of Medicinal Chemistry, offer a new path forward in the development of drugs that could potentially help cure - rather than treat - HIV.